Electrospray ionization mass spectrometric characterization of key Te(IV) cationic intermediates for the addition of TeCl4 to alkynes

Leonardo Silva Santos. Universidad de Talca, Instituto de Química de Recursos Naturales, P.O. Box 747, Talca, Chile.Tellurium tetrachloride adds to alkynes via two pathways: a concerted syn-addition that yields Z-tri- and -tetrasubstituted alkenes or an anti-addition that yields E-alkenes. The mechanistic aspects of these divergent pathways for TeCl4 addition to alkynes have been investigated by on-line electrospray ionization (tandem) mass spectrometry (ESI-MS(/MS)). Via ESI-MS(/MS), we have been able to intercept and characterize the active electrophile TeCl in tetrahydrofuran (THF) solutions of TeCl4, as well as its THF complex and several TeClx(OH) derivatives. For the first time, also, key Te(IV) cationic intermediates of the electrophilic addition of TeCl4 to alkynes were captured for gas-phase MS investigation. The detailed structural data of cyclic tellurane intermediates intercepted herein seems to provide insights into the coordinative behavior of the Te(IV) atom and its mode of action towards biological targets. Copyright © 2007 John Wiley & Sons, Ltd

Bcl-2 expression and apoptosis induction in human HL60 leukaemic cells treated with a novel organotellurium(IV) compound RT-04

Organotellurium(IV) compounds have been reported to have multiple biological activities including cysteine protease-inhibitory activity, mainly cathepsin B. As cathepsin B is a highly predictive indicator for prognosis and diagnosis of cancer, a possible antitumor potential for these new compounds is expected. In this work, it was investigated the effectiveness of organotellurium(IV) RT-04 to produce lethal effects in the human promyelocytic leukaemia cell line HL60. Using the MTT tetrazolium reduction test, and trypan blue exclusion assay, the IC50 for the compound after 24 h incubation was 6.8 and 0.35 μM, respectively. Moreover, the compound was found to trigger apoptosis in HL60 cells, inducing DNA fragmentation and caspase-3, -6, and -9 activations. The apoptsosis-induced by RT-04 is probably related to the diminished Bcl-2 expression, observed by RT-PCR, in HL60-treated cells. In vivo studies demonstrated that the RT-04 treatment (2.76 mg/kg given for three consecutive days) produces no significant toxic effects for bone marrow and spleen CFU-GM. However, higher doses (5.0 and 10 mg/kg) produced a dose-dependent reduction in the number of CFU-GM of RT-04-treated mice. These results suggest that RT-04 is able to induce apoptosis in HL60 cells by Bcl-2 expression down-modulation. Further studies are necessary to better clarify the effects of this compound on bone marrow normal cells46725402545CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPNão temNão te

Bcl-2 Expression And Apoptosis Induction In Human Hl60 Leukaemic Cells Treated With A Novel Organotellurium(iv) Compound Rt-04

Organotellurium(IV) compounds have been reported to have multiple biological activities including cysteine protease-inhibitory activity, mainly cathepsin B. As cathepsin B is a highly predictive indicator for prognosis and diagnosis of cancer, a possible antitumor potential for these new compounds is expected. In this work, it was investigated the effectiveness of organotellurium(IV) RT-04 to produce lethal effects in the human promyelocytic leukaemia cell line HL60. Using the MTT tetrazolium reduction test, and trypan blue exclusion assay, the IC50 for the compound after 24 h incubation was 6.8 and 0.35 μM, respectively. Moreover, the compound was found to trigger apoptosis in HL60 cells, inducing DNA fragmentation and caspase-3, -6, and -9 activations. The apoptsosis-induced by RT-04 is probably related to the diminished Bcl-2 expression, observed by RT-PCR, in HL60-treated cells. In vivo studies demonstrated that the RT-04 treatment (2.76 mg/kg given for three consecutive days) produces no significant toxic effects for bone marrow and spleen CFU-GM. However, higher doses (5.0 and 10 mg/kg) produced a dose-dependent reduction in the number of CFU-GM of RT-04-treated mice. These results suggest that RT-04 is able to induce apoptosis in HL60 cells by Bcl-2 expression down-modulation. Further studies are necessary to better clarify the effects of this compound on bone marrow normal cells. © 2008 Elsevier Ltd. All rights reserved.46725402545Alonso, S., Minty, A., Bourlet, Y., Buckingham, M., Comparison of three actin-coding sequences in the mouseevolutionary relationships between the actin genes of warm-blooded vertebrates (1986) J. Mol. Evol., 23, pp. 11-22Baum, C., Fairbairn, L.J., Hildinger, M., Lashford, L.S., Hegewisch-Becker, S., Rafferty, J.A., New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells (1999) Expert Rev. Mol. Med., 12, pp. 1-28Brito, J.M., Borojevic, R., Liver granulomas in schistosomiasis: mast cell-dependent induction of SCF expression in hepatic satellite cells is mediated by TNF-alpha (1997) J. Leuk. Biol., 62, pp. 389-396Cao, G., Xiao, M., Sun, F., Xiao, X., Pei, W., Li, J., Graham, S.H., Chen, J., Cloning of a novel Apaf-1-interacting protein: a potent suppressor of apoptosis and ischemic neuronal cell death (2004) J. Neurosci., 24, pp. 6189-6201Chen, F., Vallyathan, V., Castranova, V., Shi, X., Cell apoptosis induced by carcinogenic metals (2001) Mol. Cell Biochem., 222, pp. 183-188Chen, M., Wang, J., Initiator caspases in apoptosis signaling pathways (2002) Apoptosis, 4, pp. 313-319Cohen, G.M., Caspases: the executioners of apoptosis (1997) Biochem. J., 326, pp. 1-16Cunha, R.L.O.R., Urano, M.E., Chagas, J.R., Almeida, P.C., Bincoletto, C., Tersariol, I.L.S., Comasseto, J.V., Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin B (2005) Bioorg. Med. Chem. Lett., 15, pp. 755-760Engman, L., Al-Maharik, N., McNaughton, M., Birmingham, A., Powis, G., Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells (2003) Bioorg. Med. Chem., 11, pp. 5091-5100Fesik, S.W., Promoting apoptosis as a strategy for cancer drugs discovery (2005) Nat. Rev., 5, pp. 876-885Frei, G.M., Lebenthal, I., Albeck, M., Albeck, A., Sredni, B., Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake (2007) Biochem. Pharmacol., 74, pp. 712-722Hanahan, D., Weinberg, R.A., The hallmarks of cancer (2000) Cell, 100, pp. 57-70Harrison, P.R., Lanfear, J., Wu, L., Fleming, J., McGarry, L., Blower, L., Chemopreventive and growth inhibitory effects of selenium (1997) Biomed. Environ. Sci., 10, pp. 235-245Jiang, X., Wang, X., Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1 (2000) J. Biol. Chem., 275, pp. 31199-31203Liu, X., Zou, H., Slaughter, C., Wang, X., DFF a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis (1997) Cell, 89, pp. 175-184Lovschall, H., Eiskjaer, M., Arenholt-Bindslev, D., Formaldehyde cytotoxicity in three human cell types assessed in three different assays (2002) Toxicol. In Vitro, 16, pp. 63-69Malerba, I., Casati, S., Diodovich, C., Parent-Massin, D., Gribaldo, L., Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high-throughput in vitro method (2004) Toxicol. In Vitro, 3, pp. 293-300McNaughton, M., Engman, L., Birmingham, A., Powis, G., Cotgreave, I.A., Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth (2004) J. Med. Chem., 47, pp. 233-239Metcalf, D., (1984) Clonal Culture of Hemopoietic Cells: Techniques and Applications, , Elsevier, Amsterdam p. 167Minko, T., Kopecková, P., Kopecek, J., Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells (2001) J. Contr. Release, 71, pp. 227-237Mosmmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay (1983) J. Immunol. Meth., 65, pp. 55-63Newell, D.R., Silvester, J., McDowell, C., Burtles, S.S., The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies (2004) Eur. J. Cancer, 40, pp. 899-906. , Cancer Research UKNoda, Y., Suzuki, T., Kahara, A., Yotsuyanagi, A., Hasegawa, T., Hayshi, M., Sofuni, T., Okada, S., In vivo genotoxicity evaluation of dimethylarsinic in Muat™ mouse (2002) Mut. Ras. Gen Toxicol. Muagen., 513, pp. 205-212Nogueira, C.W., Zeni, G., Rocha, J.B., Organoselenium and organotellurium compounds: toxicology and pharmacology (2004) Chem. Rev., 104, pp. 6255-6285Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2005) Nature, 435, pp. 677-681Osorio, L.M., De Santiago, A., Aguilar-Santelises, M., Mellstedt, H., Jondal, M., CD6 ligation modulates Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM (1997) Blood, 89, pp. 2833-2841Pailard, F., Finot, F., Mouche, I., Perez, A., Vericat, J.A., Use of primary cultures of rat hepatocytes to predict toxicity in the early development of new chemical entities (1999) Toxicol. In vitro, 13, pp. 693-700Parent-Massin, D., Relevance of clonogenic assays in hematotoxicology (2001) Cell Biol. Toxicol., 17, pp. 87-94Pessina, A., Albella, B., Bayo, M., Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics (2003) Toxicol. Sci., 75, pp. 355-367Rinehart, J., Adjei, A.A., Lorusso, P.M., Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer (2004) J. Clin. Oncol., 22, pp. 4456-4462Rodriguez, J., Lazebnik, Y., Caspase-9 and APAF-1 form an active holoenzyme (1999) Genes Dev., 13, pp. 3179-3184Sailer, B.L., Liles, N., Dickerson, S., Sumners, S., Chasteen, T.G., Oraganotellurium compound toxicity in a promyelocytic cell line compared to non-tellurium-containing organic analog (2004) Toxicol. In vitro, 18, pp. 475-482Stewart, M.S., Davis, R.L., Walsh, L.P., Pence, B.C., Induction of differentiation and apoptosis by sodium selenite in human colonic carcinoma cells (HT29) (1997) Cancer Lett., 117, pp. 35-40Wei, M.C., Zong, W.X., Cheng, E.H., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death (2001) Science, 292, pp. 727-730Wieslander, E., Engman, L., Svensjö, E., Antioxidative properties of organotellurium compounds in cell systems (1998) Biochem. Pharmacol., 55, pp. 573-584Zeni, G., Chieffi, A., Cunha, R.L.O.R., Stefani, H.A., Zukerman-Schpector, J., Comasseto, J.V., (1999) Organometallics, 18, pp. 803-806Zimmermann, K.C., Bonzon, C., Green, D.R., The machinery of programmed cell death (2001) Pharmacol. Ther., 92, pp. 57-7